Search Results

There are 7081 results for: content related to: Abstracts of the Annual Scientific Meeting of the Australian and New Zealand College of Anaesthetists, May 3–7, Sydney, New South Wales, Australia

  1. Pharmacokinetics of Aprepitant After Single and Multiple Oral Doses in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 46, Issue 3, March 2006, Pages: 291–300, Dr Anup K. Majumdar, Ms Laura Howard, Dr Michael R. Goldberg, Ms Lisa Hickey, Mr Marvin Constanzer, Dr Paul L. Rothenberg, Ms Tami M. Crumley, Ms Deborah Panebianco, Dr Thomas E. Bradstreet, Dr Arthur J. Bergman, Dr Scott A. Waldman, Dr Howard E. Greenberg, Dr Kathleen Butler, Dr A. Knops, Dr Inge De Lepeleire, Ms Nicole Michiels and Dr Kevin J. Petty

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270005283467

  2. Effect of Aprepitant on the Pharmacokinetics of Intravenous Midazolam

    The Journal of Clinical Pharmacology

    Volume 47, Issue 6, June 2007, Pages: 744–750, Dr. Anup K. Majumdar, Ms. Kerri X. Yan, Dr. Diana V. Selverian, Dr. Suna Barlas, Mr. Marvin Constanzer, Mr. James Dru, Dr. Jacqueline B. McCrea, Ms. Tuli Ahmed, Dr. Glen S. Frick, Dr. Walter K. Kraft, Dr. Kevin J. Petty and Dr. Howard E. Greenberg

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007300807

  3. Equivalent Dynamic Human Brain NK1-Receptor Occupancy Following Single-Dose i.v. Fosaprepitant vs. Oral Aprepitant as Assessed by PET Imaging

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 2, August 2012, Pages: 243–250, K Van Laere, J De Hoon, G Bormans, M Koole, I Derdelinckx, I De Lepeleire, R Declercq, S M Sanabria Bohorquez, T Hamill, P D Mozley, D Tatosian, W Xie, Y Liu, F Liu, P Zappacosta, C Mahon, K L Butterfield, L B Rosen, M G Murphy, R J Hargreaves, J A Wagner and C R Shadle

    Version of Record online : 27 JUN 2012, DOI: 10.1038/clpt.2012.62

  4. Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers

    The Journal of Clinical Pharmacology

    Volume 46, Issue 7, July 2006, Pages: 792–801, Dr Susie Xiujiang Li, Mr Edward Pequignot, Ms Deborah Panebianco, Dr Paul Lupinacci, Dr Anup Majumdar, Dr Laura Rosen, Ms Tuli Ahmed, Dr Jane E. Royalty, Dr Thomas H. Rushmore, Dr M. Gail Murphy and Dr Kevin J. Petty

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270006288954

  5. You have free access to this content
    Aprepitant and fosaprepitant drug interactions: a systematic review

    British Journal of Clinical Pharmacology

    Volume 83, Issue 10, October 2017, Pages: 2148–2162, Priya Patel, J. Steven Leeder, Micheline Piquette-Miller and L. Lee Dupuis

    Version of Record online : 10 JUN 2017, DOI: 10.1111/bcp.13322

  6. A Single-Dose Bioequivalence and Food Effect Study With Aprepitant and Fosaprepitant Dimeglumine in Healthy Young Adult Subjects

    Clinical Pharmacology in Drug Development

    Volume 1, Issue 3, July 2012, Pages: 93–101, Craig R. Shadle, M. Gail Murphy, Yang Liu, Maureen Ho, Daniel Tatosian, Susie (Xiujiang) Li and Robert A. Blum

    Version of Record online : 10 JAN 2013, DOI: 10.1177/2160763X12447304

  7. Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation

    The Journal of Clinical Pharmacology

    Volume 52, Issue 4, April 2012, Pages: 586–594, Dr Joseph S. Bubalo, Dr Ganesh Cherala, Dr Jeannine S. McCune, Dr Myrna Y. Munar, Dr Sunny Tse and Dr Richard Maziarz

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270011398243

  8. Tolerability of Fosaprepitant and Bioequivalency to Aprepitant in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 47, Issue 7, July 2007, Pages: 834–840, Dr Kenneth C. Lasseter, Dr Jay Gambale, Dr Bo Jin, Dr Art Bergman, Mr Marvin Constanzer, Mr James Dru, Dr Tae H. Han, Dr Anup Majumdar, Dr Judith K. Evans and Dr M. Gail Murphy

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270007301800

  9. You have free access to this content
    Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting

    Cancer

    Volume 97, Issue 9, 1 May 2003, Pages: 2290–2300, Sant P. Chawla, Steven M. Grunberg, Richard J. Gralla, Paul J. Hesketh, Cindy Rittenberg, Mary E. Elmer, Carrie Schmidt, Arlene Taylor, Alexandra D. Carides, Judith K. Evans and Kevin J. Horgan

    Version of Record online : 17 APR 2003, DOI: 10.1002/cncr.11320

  10. Evaluation of Potential Inductive Effects of Aprepitant on Cytochrome P450 3A4 and 2C9 Activity

    The Journal of Clinical Pharmacology

    Volume 44, Issue 3, March 2004, Pages: 215–223, Mr Craig R. Shadle, Dr Yih Lee, Dr Anup K. Majumdar, Dr Kevin J. Petty, Ms Cynthia Gargano, Dr Thomas E. Bradstreet, Dr Judith K. Evans and Dr Robert A. Blum

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003262950

  11. You have full text access to this Open Access content
    Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin

    Cancer Science

    Volume 101, Issue 11, November 2010, Pages: 2455–2461, Toshiaki Takahashi, Eishin Hoshi, Masakazu Takagi, Noriyuki Katsumata, Masaaki Kawahara and Kenji Eguchi

    Version of Record online : 24 JUL 2010, DOI: 10.1111/j.1349-7006.2010.01689.x

  12. Pharmacokinetics of Oral Dexamethasone and Midazolam When Administered With Single-Dose Intravenous 150 mg Fosaprepitant in Healthy Adult Subjects

    The Journal of Clinical Pharmacology

    Volume 51, Issue 12, December 2011, Pages: 1712–1720, Dr Thomas C. Marbury, Ms Phung L. Ngo, Mr Craig R. Shadle, Dr Bo Jin, Ms Deborah Panebianco, Dr Luzelena Caro, Dr Jack Valentine and Dr Gail Murphy

    Version of Record online : 12 MAR 2013, DOI: 10.1177/0091270010387792

  13. Efficacy of aprepitant in management of chemotherapy-induced nausea and vomiting

    Internal Medicine Journal

    Volume 37, Issue 4, April 2007, Pages: 247–250, J. A. A. Osorio-Sanchez, C. Karapetis and B. Koczwara

    Version of Record online : 27 MAR 2007, DOI: 10.1111/j.1445-5994.2007.01311.x

  14. Aprepitant in antiemetic combinations to prevent chemotherapy-induced nausea and vomiting

    International Journal of Clinical Practice

    Volume 58, Issue 2, February 2004, Pages: 201–206, I.N. Olver

    Version of Record online : 8 MAR 2004, DOI: 10.1111/j.1368-5031.2004.0135.x

  15. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder

    Human Psychopharmacology: Clinical and Experimental

    Volume 29, Issue 6, November 2014, Pages: 568–577, William A. Ball, Duane B. Snavely, Richard J. Hargreaves, Armin Szegedi, Christopher Lines and Scott A. Reines

    Version of Record online : 20 OCT 2014, DOI: 10.1002/hup.2444

  16. Automated analysis of delayed emesis in the telemetered ferret: detection of synergistic effects of aprepitant and ondansetron

    Fundamental & Clinical Pharmacology

    Volume 28, Issue 6, December 2014, Pages: 643–651, Sonia Goineau, Philippe Guillaume, Laurence Barrais and Vincent Castagné

    Version of Record online : 19 MAY 2014, DOI: 10.1111/fcp.12082

  17. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

    Clinical Pharmacology & Therapeutics

    Volume 74, Issue 1, July 2003, Pages: 17–24, Jacqueline B. McCrea, Anup K. Majumdar, Michael R. Goldberg, Marian Iwamoto, Cynthia Gargano, Deborah L. Panebianco, Michael Hesney, Christopher R. Lines, Kevin J. Petty, Paul J. Deutsch, M. Gail Murphy, Keith M. Gottesdiener, D. Ronald Goldwater and Robert A. Blum

    Version of Record online : 19 JUL 2003, DOI: 10.1016/S0009-9236(03)00066-3

  18. Aprepitant, der erste therapeutisch wirksame NK1-Rezeptor-Antagonist. Prävention von Übelkeit und Erbrechen

    Pharmazie in unserer Zeit

    Volume 36, Issue 5, September 2007, Pages: 373–380, Karen Nieber and Konrad Schoppmeyer

    Version of Record online : 22 AUG 2007, DOI: 10.1002/pauz.200700234

  19. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled study of efficacy and tolerability

    Pediatric Blood & Cancer

    Volume 52, Issue 2, February 2009, Pages: 242–247, Lia Gore, Sant Chawla, Antonio Petrilli, Molly Hemenway, Debra Schissel, Vickey Chua, Alexandra D. Carides, Arlene Taylor, Suzanne DeVandry, Jack Valentine, Judith K. Evans and Bettina Oxenius

    Version of Record online : 4 NOV 2008, DOI: 10.1002/pbc.21811

  20. Lack of Effect of Aprepitant on Digoxin Pharmacokinetics in Healthy Subjects

    The Journal of Clinical Pharmacology

    Volume 43, Issue 8, August 2003, Pages: 912–917, Dr. Martin Feuring, Dr. Yih Lee, Ms. Laura H. Orlowski, Ms. Nicole Michiels, Dr. Marina De Smet, Dr. Anup K. Majumdar, Dr. Kevin J. Petty, Dr. Michael R. Goldberg, Dr. M. Gail Murphy, Dr. Keith M. Gottesdiener, Mr. Michael Hesney, Dr. L. Ellen Brackett and Dr. Martin Wehling

    Version of Record online : 8 MAR 2013, DOI: 10.1177/0091270003256113